Sichuan Hexie Shuangma (000935.SZ): The application for listing of acetic acid jableburi chemical raw materials has been approved.
Sichuan Shuangma (000935.SZ) announced that the company's controlling subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. (referred to as "...)
Sichuan Hexie Shuangma (000935.SZ) announced that its controlling subsidiary, Hubei Jianxiang Biological Pharmaceutical Co., Ltd. (referred to as "Hubei Jianxiang"), recently obtained the approval notice for the market application of Leuprorelin Acetate issued by the National Medical Products Administration.
The announcement shows that Leuprorelin Acetate is a gonadotropin-releasing hormone (GnRH) agonist, and continuous administration at therapeutic doses can effectively suppress the secretion of gonadotropins. Currently approved in China for the treatment of endometriosis, uterine fibroids, prostate cancer, premenopausal breast cancer with estrogen receptor positivity, and central precocious puberty.
Related Articles
JIUMAOJIU (09922) announced on October 16th that it spent HK$1.0028 million to repurchase 478,000 shares.
Central China: Three major telecommunications operators' eSIM mobile commercial trials approved, global telecommunications equipment revenue resumes growth.
Director Wang Xiaopeng of Zhejiang Heda Technology (688296.SH) plans to reduce his holdings by no more than 145,000 shares.
JIUMAOJIU (09922) announced on October 16th that it spent HK$1.0028 million to repurchase 478,000 shares.
Central China: Three major telecommunications operators' eSIM mobile commercial trials approved, global telecommunications equipment revenue resumes growth.
Director Wang Xiaopeng of Zhejiang Heda Technology (688296.SH) plans to reduce his holdings by no more than 145,000 shares.
